Background
Metastatic breast cancer (MBC) represents the most advanced stage of breast malignancy, where cancer cells have spread beyond the breast and regional lymph nodes to distant organs. Despite advances in systemic therapies including hormonal therapy, chemotherapy, and targeted agents, MBC remains largely incurable, with a 5-year survival rate of approximately 30%. Treatment decisions in this setting are critically important, as ineffective therapy not only fails to control disease but also exposes patients to unnecessary toxicity and diminishes quality of life.
The current standard approach to monitoring treatment response relies primarily on computed tomography (CT) imaging performed after 8-12 weeks of therapy. However, this delayed assessment window may postpone recognition of treatment failure, prolonging exposure to ineffective agents. Furthermore, CT primarily evaluates anatomical changes, which may lag behind actual tumor metabolic activity. This limitation has spurred interest in functional imaging modalities that can detect early biological changes in response to therapy.
18F-fluorodeoxyglucose positron emission tomography (FDG-PET) offers a fundamentally different approach to assessing treatment response. By measuring cellular glucose metabolism—a hallmark of cancer cell activity—FDG-PET can potentially identify treatment effects within days rather than weeks. A metabolic response detectable on FDG-PET may precede visible structural changes on CT, offering clinicians a window of opportunity to adjust therapeutic strategies earlier.
Study Design
The IMPACT-MBC (IMaging Platform for Assessing Chemosensitivity of Tumors in Metastatic Breast Cancer) clinical cohort trial was a multicenter study conducted across multiple academic medical centers. The trial enrolled 200 patients with nonrapidly progressive, newly diagnosed MBC between August 2013 and May 2018, prior to initiation of first-line systemic therapy.
Eligible participants underwent comprehensive baseline assessment including metastatic site biopsy, FDG-PET imaging, and CT scanning. Following initiation of standard first-line systemic therapy, patients underwent early FDG-PET after just 2 weeks of treatment. Standard CT response evaluation was performed at 8 weeks according to Response Evaluation Criteria in Solid Tumors (RECIST).
The study evaluated the clinical utility of early FDG-PET defined as its capacity to estimate three key outcomes: progressive disease (PD) on 8-week CT, progression-free survival (PFS), and overall survival (OS). Patients were categorized based on metabolic response status on early FDG-PET and anatomical response on subsequent CT imaging.
Key Findings
The analysis included 200 patients with a median age of 61 years (range 32-84), comprising 198 females (99%) and 2 males (1%). The study population reflected the heterogeneity of MBC, including all major molecular subtypes and both visceral and non-visceral metastatic disease patterns.
The primary finding demonstrated that non-progressive disease (non-PD) on early FDG-PET achieved a negative predictive value (NPV) of 94.7% (95% CI, 89.5%-97.4%) for non-PD on 8-week CT. This high predictive accuracy was consistent across all breast cancer subtypes and importantly, remained robust in patients with bone-only metastatic disease—a traditionally challenging subgroup for response assessment.
Among patients receiving standard-of-care treatment who demonstrated non-PD on early FDG-PET (n=133), outcomes were markedly superior compared to those with PD on early imaging. Median progression-free survival reached 19.4 months (95% CI, 15.2-22.8) versus only 4.1 months (95% CI, 3.3-15.5) in the PD group. Overall survival similarly favored the non-PD group at 39.4 months (95% CI, 33.7-48.3) compared to 18.5 months (95% CI, 7.0-33.0). These differences achieved statistical significance with P values less than 0.001 for both endpoints.
Perhaps most clinically relevant, among patients with non-PD on 8-week CT (indicating disease control by standard assessment), those with PD on early FDG-PET showed substantially worse outcomes. This discordant group experienced median PFS of 9.5 months (IQR 4.1-18.1) and OS of 19.4 months (IQR 8.7-33.0), compared to 22.3 months (IQR 15.3-96.1) and 40.1 months (IQR 23.4-72.7) respectively in patients without early metabolic progression. This finding suggests early FDG-PET can identify patients destined for early relapse despite achieving initial disease control on conventional imaging.
Subgroup Analysis Summary
The prognostic value of early FDG-PET remained consistent regardless of hormone receptor status, HER2 expression, or dominant site of metastatic disease. The 94.7% negative predictive value provides clinicians with high confidence that patients showing metabolic response at 2 weeks will maintain disease control at 8 weeks, enabling more informed discussions about treatment expectations with patients.
Expert Commentary
The IMPACT-MBC trial represents a significant advancement in the application of molecular imaging for precision oncology. By demonstrating that FDG-PET performed as early as 2 weeks into treatment provides powerful prognostic information, this study challenges the conventional paradigm of delayed response assessment in metastatic breast cancer.
Several methodological strengths support the validity of these findings. The multicenter design enhances generalizability, while the predefined clinical utility endpoint provides clinically meaningful outcome measures rather than merely surrogate markers. The consistency of findings across molecular subtypes and metastatic patterns strengthens confidence in broad applicability.
However, important limitations warrant consideration. The study was nonrandomized, precluding definitive conclusions about whether earlier treatment modification based on FDG-PET findings would actually improve outcomes. The patient population excluded those with rapidly progressive disease, limiting insights into the most aggressive presentations. Additionally, while FDG-PET identified patients at higher risk, whether intensifying or switching therapy in response to early metabolic progression improves outcomes remains to be demonstrated.
The biological basis for these findings relates to the fundamental principle that effective anticancer therapy rapidly reduces cellular glucose metabolism before causing measurable tumor volume changes. FDG-PET therefore captures the “death signal” of responding tumors earlier than anatomical imaging, explaining its superior prognostic discrimination at early timepoints.
Conclusion
The IMPACT-MBC trial establishes early FDG-PET as a powerful prognostic tool in newly diagnosed metastatic breast cancer. A simple metabolic imaging assessment performed just 2 weeks after initiating systemic therapy can accurately stratify patients into distinct prognostic groups with markedly different survival expectations. With a negative predictive value approaching 95%, clinicians can confidently reassure patients showing early metabolic response about likely disease control at the conventional 8-week assessment point.
The ability of early FDG-PET to identify treatment failure before it becomes anatomically apparent offers potential for earlier therapeutic pivots, potentially improving outcomes by avoiding prolonged exposure to ineffective agents. However, prospective trials testing treatment modification strategies based on early FDG-PET findings are needed to confirm clinical benefit.
For clinical practice, these findings support consideration of early FDG-PET as a valuable complement to conventional response assessment, particularly when treatment decisions require earlier confirmation of efficacy. The IMPACT-MBC data provide robust evidence supporting the integration of metabolic imaging into routine metastatic breast cancer management.
Funding and Trial Registration
This study was supported by the Dutch Cancer Society (Koningin Wilhelmina Fonds). The trial was registered at ClinicalTrials.gov under identifier NCT01957332.
References
1. van Geel JJL, Eisses B, Elias SG, et al. 18F-Fluorodeoxyglucose Positron Emission Tomography for Estimating Outcomes After Initial Treatment for Metastatic Breast Cancer: A Nonrandomized Clinical Cohort Trial. JAMA Oncol. 2026. PMID: 41989806.
